Nearly one in 20 people who had a SARS-CoV-2 infection go on to experience myalgic encephalomyelitis/chronic fatigue syndrome ...

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao ...

Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in ...

The risk for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is increased following COVID-19, according to study findings.

Vaccination prior to COVID-19 infection does not significantly affect neurological symptoms in patients with postacute sequelae of SARS-CoV-2 infection.

Adriel Chen and Devi Sridhar discuss the outbreak of Paediatric Inflammatory Multisystem Syndrome in 2020 and consider what lessons we can learn In mid-March 2020 and into April 2020, paediatric wards ...

According to the researchers, Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating condition that is ...

New findings from the NIH RECOVER Initiative suggest that SARS-CoV-2 infection may be associated with an increased risk of ME ...

A recent University of Utah Health study found that 4.5% of Covid-19 survivors developed chronic fatigue syndrome, a ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Jay Bhattacharya Will Bring Transparency to NIH . Dr. Andrew Noymer is an epidemiologist and population health scientist who ...